Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $365
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Biogen and raises the price target from $343 to $365.
November 09, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo maintains an Overweight rating on Biogen and raises the price target from $343 to $365, which could positively impact the stock.
The raised price target by Wells Fargo indicates a positive outlook for Biogen. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100